(Q37906364)

25 August 2017

1 reference

title

Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy (English)

1 reference

25 August 2017

2

Wolfgang H Oertel

1 reference

25 August 2017

Vincent Ries

1

1 reference

25 August 2017

Günter U Höglinger

series ordinal

3

1 reference

25 August 2017

publication date

27 July 2011

1 reference

Journal of Molecular Neuroscience

25 August 2017

published in

1 reference

25 August 2017

volume

45

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

684-689

1 reference

Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Further evidence for mitochondrial dysfunction in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Expression and activity of antioxidants in the brain in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Assessing the effects of age on long white matter tracts using diffusion tensor tractography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Peptide neuroprotection through specific interaction with brain tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

The FAB: a Frontal Assessment Battery at bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

DTI-based three-dimensional tractography detects differences in the pyramidal tracts of infants and children with congenital hemiparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

A clinical rating scale for progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Tau Pathology and Future Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Addressing Alzheimer's disease tangles: from NAP to AL-108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Mechanisms of tau-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Oxidative stress and the pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Transgenic animal models of tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Mitochondrial Complex I: structural and functional aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Creatine and cyclocreatine attenuate MPTP neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

White matter pathology isolates the hippocampal formation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Cerebral oxygen metabolism in patients with progressive supranuclear palsy: a positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Origin and functional consequences of the complex I defect in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Current and future treatments in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-011-9606-3

Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress

21 January 2018

1 reference

12 December 2020

Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes

1 reference

12 December 2020

Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease

1 reference

12 December 2020

Dietary supplement creatine protects against traumatic brain injury

1 reference

12 December 2020

Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly

1 reference

12 December 2020

Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography

1 reference

12 December 2020

NAP protects against cyanide-related microtubule destruction

1 reference

12 December 2020

Threshold effects in synaptosomal and nonsynaptic mitochondria from hippocampal CA1 and paramedian neocortex brain regions.

1 reference

12 December 2020

Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.

1 reference

12 December 2020

Muscle mitochondrial ATP production in progressive supranuclear palsy

1 reference

12 December 2020

Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10

1 reference

12 December 2020

Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe

1 reference

12 December 2020

Lipoperoxidation is selectively involved in progressive supranuclear palsy

1 reference

12 December 2020

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

1 reference

12 December 2020

Changes in white matter microstructure in patients with TLE and hippocampal sclerosis

1 reference

12 December 2020

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

12 December 2020

Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia

1 reference

12 December 2020

10.1007/S12031-011-9606-3

Identifiers

DOI

1 reference

25 August 2017

1 reference